KAYSOTCPharmaceutical PreparationsUS GAAP · USD

Kaya Holdings, Inc.

Kaya Holdings, Inc. is a U.S.-based cannabis and emerging psychedelics operator that runs retail sales, cultivation-related projects, and service activities through a network of majority-owned subsidiaries. The company also has a newer digital-assets treasury initiative, but its current business remains centered on cash-and-carry cannabis retail and development-stage cannabis/psychedelic operations.

Liikevaihto0,0milj. USD
−96,4 %v/v
Liikevoitto (EBIT)−2,0milj. USD
−97,7 %v/v
EBIT-marginaali−28 343,5%
−27 822,5 %-yks.v/v
Nettotulos−2,1milj. USD
−229,3 %v/v
Vapaa kassavirta−0,9milj. USD
+18,0 %v/v

Tilikausi 2024 · muutos edellisvuodesta

Kehitys 2019–2024

−3−2−1012milj. USD2019: 1,0 milj. USD2019: EBIT −2,3 milj. USD20192020: 1,0 milj. USD2020: EBIT −1,8 milj. USD20202021: 0,89 milj. USD2021: EBIT −1,4 milj. USD20212022: 0,69 milj. USD2022: EBIT −1,7 milj. USD20222023: 0,20 milj. USD2023: EBIT −1,0 milj. USD20232024: 0,01 milj. USD2024: EBIT −2,0 milj. USD20240,01−2,0
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Cannabis retail70 %

Cash-and-carry sales of cannabis products through licensed retail locations.

Cannabis cultivation and processing development10 %

Development-stage cultivation, extraction, packing, and related infrastructure projects, mainly in Greece.

Psychedelic services10 %

OHA-licensed psilocybin service center activities and related facilitation services.

Licensing and pilot studies5 %

Contract-based revenue from licensing agreements and pilot studies.

Ancillary services5 %

ATM transaction fees and other small ancillary revenue streams at operating sites.

Asiakkaat

Kaya sells primarily to adult-use cannabis consumers at licensed retail stores, where transactions are completed immediately in cash or card for services. It also targets medical cannabis and future international cannabis customers through its Greek subsidiary, while its psychedelic service center is aimed at patients or clients seeking regulated psilocybin facilitation services. Smaller revenue streams come from counterparties in licensing, pilot-study, and ATM-service arrangements.

Cannabis retail consumers

Buy cannabis products at licensed stores on a cash-and-carry basis for immediate consumption or use.

Medical cannabis market participants

Buy cultivation, extraction, and processing output from the company's overseas cannabis platform as it develops.

Psilocybin service clients

Purchase regulated psilocybin facilitation services at the company's licensed service center.

Licensing and pilot-study partners

Enter contracts for product commercialization, licensing, or pilot studies tied to the company's development pipeline.

ATM service counterparties

Provide ancillary fee income from ATM transactions at retail locations.

Strategia

Management is trying to fund and complete its growth projects while sustaining current retail operations and preserving liquidity. The strategy combines domestic cash-generating cannabis retail with overseas cannabis expansion in Greece, plus a newer psychedelic-treatment platform and a digital-assets treasury initiative. Near-term execution depends heavily on raising capital and converting development assets into operating revenue.

Raise additional capitalLyhyt aikaväli

The company needs financing to fund operations, complete projects, and bridge working-capital deficits.

Complete Greece cannabis projectKeskipitkä aikaväli

The Epidaurus site could add cultivation, extraction, and packing capacity if financed and completed.

Develop psychedelic treatment operationsKeskipitkä aikaväli

This creates a second regulated healthcare-adjacent growth avenue beyond cannabis retail.

Broaden the business modelPitkä aikaväli

Management is adding new platforms to reduce dependence on a narrow retail base.

Maantiede

Kaya is headquartered in the United States and operates mainly through Florida, Oregon, and other U.S. subsidiaries, with additional exposure to Israel and Greece through majority-owned international entities. Its Greece project is a major strategic geography, designed for cultivation, extraction, and packing, but it remains development-stage and dependent on financing. The company also has a newly formed crypto operations subsidiary in Florida, though that initiative is still early.

Riskit

Kaya faces substantial going-concern, financing, and execution risk because it has limited cash, a working-capital deficit, and development projects that require outside funding. Its cannabis operations are exposed to regulatory constraints, Section 280E tax treatment, and volatile pricing and competition, while the international project pipeline adds geopolitical and project-completion risk. The company also depends on successful commercialization of new products and services that are still early in their lifecycle.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Going-concern / business failure risk1Financing and dilution risk2Cannabis regulatory and tax risk3Commercialization risk4Geopolitical / project-delivery risk5Competition and pricing pressure6
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Going-concern / business failure riskVaikutus: KriittinenTodennäköisyys: Korkea

    The company disclosed limited cash and a working-capital deficiency, making continued operations dependent on new funding.

    Kohdistuu: Corporate liquidity and all operating subsidiaries

  2. Financing and dilution riskVaikutus: KorkeaTodennäköisyys: Korkea

    Operations and project completion rely on future equity or debt raises, which may be unavailable or highly dilutive.

    Kohdistuu: Expansion projects and general working capital

  3. Cannabis regulatory and tax riskVaikutus: KorkeaTodennäköisyys: Matala

    Cannabis operations are subject to changing state/federal rules and Section 280E limits on deductions.

    Kohdistuu: U.S. cannabis retail and related discontinued cannabis activities

  4. Commercialization riskVaikutus: KeskitasoTodennäköisyys: Korkea

    Management cited uncertainty around product commercialization and ultimate success.

    KohdistuuRetail expansionPsilocybin servicesOverseas cannabis projects
  5. Geopolitical / project-delivery riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    The Greece project has already been delayed by COVID-19 and the Russia/Ukraine war, showing external disruption risk.

    KohdistuuEpidaurusGreece development project
  6. Competition and pricing pressureVaikutus: KeskitasoTodennäköisyys: Matala

    Retail cannabis markets are competitive and product pricing can be volatile, pressuring margins.

    Kohdistuu: Cannabis retail operations

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition timing

Retail sales are recognized only when product is delivered and paid for, making reported revenue sensitive to store traffic and cash collection.

Vaikutus: Quarterly revenue can be volatile and highly dependent on transaction timing.

Inventory and cost of sales

Cost of sales includes product purchases and third-party testing, which directly affects gross margin in a price-competitive market.

Vaikutus: Margin volatility if product costs or testing costs rise.

Convertible debt and debt discounts

The company records original issue discounts and amortizes them to interest expense, which can materially increase reported financing costs.

Vaikutus: Higher non-cash interest expense and dilution from conversions.

Stock-based compensation

Equity awards are measured at fair value and expensed over service periods, affecting operating losses.

Vaikutus: Non-cash compensation can materially widen reported losses.

Section 280E tax accounting

Cannabis-related operations may face limited deductibility of expenses, creating tax provisions even with net operating losses.

Vaikutus: Tax expense may not track pre-tax profitability.

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Päivitetty: 24.9.2026

Kaya Holdings, Inc. (OTC) – Pharmaceutical Preparations | Analyysi – Clarifo